Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in Cameroon

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 2, 2008, Pages 216-219

  Kouanfack, Charles ^a   Laurent, Christian ^b   Peytavin, Gilles ^c   Ciaffi, Laura ^d   Ngolle, Maguy ^e   Nkene, Yvette Mawamba ^a   Essomba, Claudine ^a   Calmy, Alexandra ^d   Mpoudi Ngolé, Eitel ^e   Delaporte, Eric ^b   Koulla Shiro, Sinata ^a  

^a YAOUNDÉ CENTRAL HOSPITAL   (Cameroon)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c BICHAT HOSPITAL   (France)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e Military Hospital   (Cameroon)

Author keywords

Adherence; Antiretroviral therapy; Drug level monitoring; HIV; Self report; Sub Saharan Africa; Viral load

Indexed keywords

LAMIVUDINE; NEVIRAPINE; STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CAMEROON; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG MONITORING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SELF REPORT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VIRUS LOAD; ADULT; BLOOD; DRUG COMBINATION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; VIROLOGY;

ADULT; ANTI-HIV AGENTS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; NEVIRAPINE; PATIENT COMPLIANCE; VIRAL LOAD;

EID: 46449108067     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181743955     Document Type: Article

References (20)

1. Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002; 34:1115-1121.
2. Sethi AK, Celentano DD, Gange SJ, et al. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003;37:1112-1118.
3. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279:1977-1983.
4. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1): S79-S87.
5. Gill CJ, Hamer DH, Simon JL, et al. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS. 2005;19: 1243-1249.
6. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353:487-497.
7. Orrell C, Bangsberg DR, Badri M, et al. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS. 2003;17:1369-1375.
8. Lanièce I, Ciss M, Desclaux A, et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS. 2003; 17(Suppl 3):S103-S108.
9. Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004;36:1100-1102.
10. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006; 43:78-84.
11. Bell DJ, Kapitao Y, Sikwese R, et al. Adherence to antiretroviral therapy in patients receiving free treatment from a government hospital in Blantyre, Malawi. J Acquir Immune Defic Syndr. 2007;45:560-563.
12. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006; 296:679-690.
13. van Oosterhout JJ, Bodasing N, Kumwenda JJ, et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health. 2005;10:464-470.
14. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet. 2004;364:29-34.
15. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine. AIDS. 2007;21:768-771.
16. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDs. 2003;17:169-177.
17. Van Heeswijk RP, Hoetelmans RM, Meenhorst PL, et al. Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1998;713:395-399.
18. Chaix ML, Ekouevi DK, Peytavin G, et al. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children. Antimicrob Agents Chemother. 2007;51:896-901.
19. Murphy R, Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Expert Opin Investig Drugs. 1996;5:1183-1199.
20. WHO. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach. 2006 revision. Available at: http://www.who.int/hiv/ pub/guidelines/artadultguidelines.pdf. 2006. Accessed October 18, 2007.